JBM (Healthcare) (HKG:2161) expects profit attributable to shareholders to increase at least 50% for the six months ended Sept. 30 compared with the corresponding period of the previous year, according to a Friday filing with the Hong Kong bourse.
The company attributed the increase in profit to the robust sales momentum of the group's key brands, notably Ho Chai Kung in the branded medicines segment and Po Chai Pills in the proprietary Chinese medicines segment, supported by the sustained growth of the group's concentrated Chinese medicine granules business.
The company plans to publish its interim results on Nov. 19.
The Medicine company's shares were up about 22% at the close of trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。